By Counterforce Health Team in Naglazyme (galsulfase) —

How to Get Naglazyme (Galsulfase) Covered by Cigna in California: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Naglazyme (Galsulfase) Covered by Cigna in California

Cigna requires prior authorization for Naglazyme (galsulfase) with strict medical necessity criteria. You'll need confirmed MPS VI diagnosis via enzyme assay/genetic testing, specialist prescriber, baseline functional assessments, and medical necessity letter. If denied, California offers powerful Independent Medical Review (IMR) with 55-68% overturn rates for specialty drugs. First step: Have your specialist complete Cigna's Naglazyme CCRD Prior Authorization Form with all diagnostic proof attached.

Table of Contents

  1. Coverage at a Glance
  2. Policy Overview
  3. Indication Requirements
  4. Step Therapy & Exceptions
  5. Quantity and Frequency Limits
  6. Required Diagnostics
  7. Site of Care Requirements
  8. Evidence to Support Medical Necessity
  9. Sample Medical Necessity Narrative
  10. Appeals Playbook for California
  11. Common Denial Reasons & Fixes
  12. Costs & Savings Options
  13. FAQ

Coverage at a Glance

Requirement What It Means Where to Find It Source
Prior Authorization Required for all Cigna plans Specialty PA form needed Cigna Policy
Formulary Status PA-restricted specialty drug Check plan's drug list Cigna Formulary
Diagnosis Required Confirmed MPS VI only Enzyme assay + genetic test FDA Label
Specialist Required Genetics/metabolism specialist Provider credentials needed Cigna PA Form
Dosing Limits 1 mg/kg IV weekly maximum Weight-based quantity limits FDA Dosing
Appeals Deadline 180 days for internal appeal California IMR within 6 months DMHC

Policy Overview

Cigna treats Naglazyme (galsulfase) as a specialty drug requiring prior authorization across all plan types—commercial HMO/PPO, Medicare Advantage, and employer group plans. The drug is typically managed through Express Scripts/Accredo specialty pharmacy and requires strict adherence to medical necessity criteria.

Plan Types and Coverage

  • Commercial Plans: Full prior authorization process with 72-hour standard review
  • Medicare Advantage: Similar criteria with CMS formulary exception rights
  • Employer Groups: May have slightly different forms but same core requirements

All Cigna plans in California are subject to the state's robust consumer protection laws, including Independent Medical Review (IMR) rights through the Department of Managed Health Care (DMHC).

Indication Requirements

Naglazyme is FDA-approved exclusively for Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome) as enzyme replacement therapy. Cigna's medical policy strictly limits coverage to this indication.

Required Documentation

  • Primary diagnosis: MPS VI with ICD-10 code E76.29
  • Enzyme confirmation: Deficient arylsulfatase B (ARSB) activity (<10% of normal)
  • Genetic testing: Biallelic pathogenic ARSB variants (when available)
  • Clinical manifestations: Documented disease progression and functional impact
Note: Off-label use for other MPS types is not covered and requires formulary exception process.

Step Therapy & Exceptions

Unlike many specialty drugs, Naglazyme typically doesn't require step therapy because it's the only FDA-approved enzyme replacement therapy for MPS VI. However, Cigna may require documentation that supportive care alone is insufficient.

Medical Exception Pathways

Cigna allows step therapy overrides when:

  • Required step drugs are contraindicated
  • Patient has tried formulary alternatives with documented failure
  • Current therapy is working and switching poses clinical risk

Submit exceptions using Cigna's formulary exception process with detailed clinical rationale.

Quantity and Frequency Limits

Cigna enforces strict quantity limits based on FDA-approved dosing:

Dosing Parameters

  • Standard dose: 1 mg/kg IV once weekly
  • Vial strength: 5 mg per 5 mL vial
  • Calculation: Patient weight (kg) × 1 mg/kg ÷ 5 mg/vial = weekly vials needed
  • Rounding: Always round up to next whole vial

Renewal Requirements

  • Updated weight documentation every 6-12 months for pediatric patients
  • Clinical benefit assessment with objective measures
  • Adherence to weekly infusion schedule
Example: A 25 kg patient would be approved for 5 vials per week (25 kg × 1 mg/kg = 25 mg ÷ 5 mg/vial = 5 vials).

Required Diagnostics

Cigna requires comprehensive baseline and ongoing assessments to establish medical necessity and monitor treatment response.

Baseline Requirements

  • 6-minute walk test: Functional capacity measurement
  • Pulmonary function tests: FVC and other respiratory parameters
  • Cardiac evaluation: Echocardiogram for valve disease assessment
  • Urinary GAGs: Elevated dermatan sulfate levels
  • Growth parameters: Height, weight, developmental milestones

Ongoing Monitoring

  • Repeat functional assessments every 6-12 months
  • Documentation of clinical stability or improvement
  • Infusion reaction monitoring and management

The MPS Society diagnostic guidelines provide detailed assessment protocols that align with Cigna's requirements.

Site of Care Requirements

Naglazyme must be administered in facilities equipped to manage severe allergic reactions, as infusion-related reactions are common.

Approved Settings

  • Hospital-based infusion centers: Preferred for complex patients
  • Outpatient infusion centers: Must have emergency protocols
  • Home infusion: Only with trained nursing and emergency access

Documentation Needed

  • Facility certification and emergency preparedness
  • Nursing competency in ERT administration
  • Access to resuscitation equipment and protocols

Cigna requires justification for higher-cost settings when lower-acuity options are medically appropriate.

Evidence to Support Medical Necessity

Building a strong evidence base is crucial for approval, especially given Naglazyme's high cost ($600K-$1.8M+ annually).

Clinical Guidelines

  • FDA prescribing information for dosing and administration
  • International MPS consensus statements on ERT initiation
  • Specialty society guidelines for lysosomal storage disorders

Peer-Reviewed Evidence

  • Clinical trial data showing walking capacity improvements
  • Real-world evidence studies on functional outcomes
  • Safety data on long-term ERT use

Documentation Tips

  • Cite specific guideline recommendations
  • Include abstracts of key studies
  • Reference manufacturer's clinical data summaries

Sample Medical Necessity Narrative

Here's a template paragraph structure for medical necessity letters:

"[Patient name] is a [age]-year-old with genetically confirmed MPS VI (ARSB gene mutations) presenting with [specific manifestations]. Baseline 6-minute walk distance of [X] meters is significantly below age-matched norms, with documented [cardiac/pulmonary/skeletal] involvement. Enzyme assay confirmed severe ARSB deficiency at [value] (normal [range]). Without ERT, patients with this phenotype experience progressive [specific complications] leading to [outcomes]. Naglazyme at 1 mg/kg weekly is the only FDA-approved therapy for MPS VI and has demonstrated [specific benefits] in clinical trials. Delay in treatment risks irreversible [organ system] damage."

Tip: Always include objective measures and avoid subjective language like "seems to help."

Appeals Playbook for California

California offers some of the strongest patient appeal rights in the nation, with high success rates for specialty drug denials.

Internal Appeal Process

  1. File within 180 days of denial notice
  2. Submit via Cigna member portal or fax
  3. Include updated medical necessity letter addressing denial reasons
  4. Request expedited review if clinically urgent (24-72 hour decision)

Independent Medical Review (IMR)

California's DMHC provides binding external review with impressive success rates:

  • Overall specialty drug overturn rate: 68%
  • Medical necessity denials: 55.3% overturned in 2023
  • No cost to patients
  • 45-day standard review, 7-day urgent

Filing IMR

  • Must complete internal appeal first (or show serious health risk)
  • Apply within 6 months of final denial
  • Submit online at DMHC Help Center or call 888-466-2219
  • Include all medical records and specialist letters
Success Factor: Cases with robust specialist documentation and guideline citations have the highest overturn rates.

Common Denial Reasons & Fixes

Denial Reason How to Fix Required Documentation
"Diagnosis not confirmed" Submit enzyme assay + genetic testing Lab reports showing ARSB deficiency
"Not medically necessary" Provide functional data showing impairment 6-minute walk test, PFTs, clinical notes
"Experimental/investigational" Cite FDA approval and guidelines FDA label, consensus statements
"No prior therapies tried" Document that no alternatives exist for MPS VI Literature review, specialist letter
"Inappropriate site of care" Justify infusion setting requirements Facility protocols, reaction history

Costs & Savings Options

Naglazyme's high cost makes financial assistance crucial for many families.

Manufacturer Support

  • BioMarin RareConnections: Patient support program
  • Copay assistance: May reduce out-of-pocket costs
  • Free drug programs: For qualifying uninsured patients

Foundation Grants

  • National Organization for Rare Disorders (NORD)
  • HealthWell Foundation
  • Patient Access Network Foundation

State Programs

  • California's Genetically Handicapped Persons Program
  • Regional center services for developmental disabilities

Contact BioMarin RareConnections for current program details and eligibility requirements.

FAQ

How long does Cigna prior authorization take in California? Standard PA decisions are made within 72 hours. Expedited reviews for urgent cases are completed within 24 hours.

What if Naglazyme is not on my Cigna formulary? You can request a formulary exception with medical necessity documentation. California law provides strong appeal rights if initially denied.

Can I request an expedited appeal? Yes, if delay would seriously jeopardize your health or if you're currently on the medication. Expedited appeals are decided within 24-72 hours.

Does step therapy apply if I failed treatments outside California? Yes, Cigna accepts documented treatment failures from other states. Include records showing specific drugs tried, dates, and reasons for discontinuation.

What happens if Cigna denies my IMR appeal? IMR decisions are binding on Cigna. If approved, they must cover the treatment. Very few IMR decisions are overturned on legal challenge.

How do I find a qualified MPS specialist in California? Contact the MPS Society for referrals to geneticists and metabolic specialists experienced with lysosomal storage disorders.

About Counterforce Health

Counterforce Health specializes in turning insurance denials into successful appeals for complex specialty medications like Naglazyme. Our platform analyzes denial letters, identifies coverage gaps, and creates evidence-backed appeals tailored to each payer's specific requirements. We help patients, clinicians, and specialty pharmacies navigate the prior authorization process with higher approval rates and faster resolutions.

From our advocates: "We've seen MPS VI families wait months for Naglazyme approval, only to succeed on appeal with the right documentation. The key is understanding exactly what Cigna's medical reviewers need to see—confirmed diagnosis, functional impairment data, and clear evidence that ERT is the only appropriate treatment. When families come prepared with this evidence package, approval rates improve dramatically."

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and may change. Always consult with your healthcare provider and insurance plan for the most current requirements. For assistance with insurance appeals in California, contact the DMHC Help Center at 888-466-2219.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.